AstraZeneca Submits Atacand For Heart Failure; First ARB To Affect Mortality
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
AstraZeneca’s Atacand supplemental NDA filing for a chronic heart failure claim is based on the first heart failure study to demonstrate a clear mortality benefit with an angiotensin-II receptor blocker.